Comprehensive Analysis of Inhibitor of Apoptosis Protein Expression and Prognostic Significance in Non–Small Cell Lung Cancer

Inhibitors of apoptosis proteins (IAPs) have been associated with tumor development and progression by affecting apoptosis through cell death signaling pathways. To date, eight IAPs (BIRC1–8) have been identified in mammalian cells. However, the role of IAPs in non–small cell lung cancer (NSCLC) development and progression has not been explored in depth. In this study, we used public datasets and bioinformatics tools to compare the expression, prognostic significance, and function of IAPs in NSCLC and its subtypes. Expression of IAPs in cancer and normal tissues and at different stages of NSCLC was compared with gene expression profiling interactive analysis, and their prognostic significance was analyzed with the Kaplan–Meier Plotter database. The correlations among IAPs were analyzed with the STRING database and SPSS19.0. Functional annotation of IAPs was analyzed by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment on the basis of the DAVID tool. Among patients with lung adenocarcinoma (LUAD), the expression level of BIRC5 was higher than that in normal samples, and the expression of BIRC1 and BIRC5 significantly varied in different stages. Moreover, the BIRC1–3 and BIRC5 mRNA levels were associated with overall survival (OS), and the BIRC1–2 and BIRC5–6 mRNA levels were associated with progression-free survival (PFS). Among patients with lung squamous cell carcinoma (LUSC), the expression level of BIRC1 was lower and that of BIRC5 was higher than those in normal tissues, and BIRC5 expression significantly varied in different stages. BIRC1 expression was associated with OS, whereas BIRC2 and BIRC6 expression was associated with PFS. Enrichment analysis showed that most IAPs are associated with ubiquitin- and apoptosis-related pathways. Collectively, this study suggests BIRC5 as a potential diagnostic and staging marker, BIRC1 as a potential marker of OS, and BIRC2 and BIRC6 as potential PFS markers for patients with NSCLC. These highlight new targets for the early detection, treatment, and management of NSCLC.

[1]  D. Danino,et al.  Multifunctional silica-coated mixed polymeric micelles for integrin-targeted therapy of pediatric patient-derived glioblastoma. , 2021, Materials science & engineering. C, Materials for biological applications.

[2]  C. Lengner,et al.  Dll1+ quiescent tumor stem cells drive chemoresistance in breast cancer through NF-κB survival pathway , 2021, Nature communications.

[3]  R. Frazzi.  BIRC3 and BIRC5: multi‐faceted inhibitors in cancer , 2021, Cell & bioscience.

[4]  Yu Zhang,et al.  Mechanism of Hydrogen Gas Promoted Apoptosis of Lung Adenocarcinoma A549 cells through XIAP and BIRC3 , 2020 .

[5]  F. Zhu,et al.  Survivin expression and impact on head and neck cancer outcomes. , 2020, Oral oncology.

[6]  A. Misra,et al.  Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I , 2020, Expert opinion on drug delivery.

[7]  Fei Zhang,et al.  Thevebioside, the active ingredient of traditional Chinese medicine, promotes ubiquitin-mediated SRC-3 degradation to induce NSCLC cells apoptosis. , 2020, Cancer letters.

[8]  Xiaoli Ma,et al.  α5‐nAChR and survivin: Two potential biological targets in lung adenocarcinoma , 2020, Journal of cellular physiology.

[9]  E. Kure,et al.  Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy , 2020, International journal of cancer.

[10]  J. Herman,et al.  Detection of Promoter DNA Methylation in Urine and Plasma Aids the Detection of Non–Small Cell Lung Cancer , 2020, Clinical Cancer Research.

[11]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[12]  J. Pujol,et al.  Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial , 2019, Cancers.

[13]  K. Rabe,et al.  Live and let die: epigenetic modifications of Survivin and Regucalcin in non-small cell lung cancer tissues contribute to malignancy , 2019, Clinical Epigenetics.

[14]  M. Rahouma,et al.  Effect of serum survivin on survival among non-small cell lung cancer patients: NCI experience , 2019, Annals of Oncology.

[15]  Xiaofei Huang,et al.  Artemether attenuates the progression of non-small cell lung cancer by inducing apoptosis, cell cycle arrest and promoting cellular senescence. , 2019, Biological & pharmaceutical bulletin.

[16]  Wanqing Chen,et al.  Prognostic Value of BIRC5 in Lung Adenocarcinoma Lacking EGFR, KRAS, and ALK Mutations by Integrated Bioinformatics Analysis , 2019, Disease markers.

[17]  P. Liu,et al.  NOD-like receptor signaling in inflammation-associated cancers: From functions to targeted therapies. , 2019, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[18]  Sung-Hoon Kim,et al.  Galbanic acid potentiates TRAIL induced apoptosis in resistant non‐small cell lung cancer cells via inhibition of MDR1 and activation of caspases and DR5 , 2019, European journal of pharmacology.

[19]  Chuan Wang,et al.  SKP2 promotes breast cancer tumorigenesis and radiation tolerance through PDCD4 ubiquitination , 2019, Journal of Experimental & Clinical Cancer Research.

[20]  Sung-Hoon Kim,et al.  Lambertianic Acid Sensitizes Non-Small Cell Lung Cancers to TRAIL-Induced Apoptosis via Inhibition of XIAP/NF-κB and Activation of Caspases and Death Receptor 4 , 2018, International journal of molecular sciences.

[21]  Dajun Yang,et al.  XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells , 2018, Theranostics.

[22]  M. Gharabaghi.  Diagnostic investigation of BIRC6 and SIRT1 protein expression level as potential prognostic biomarkers in patients with non‐small cell lung cancer , 2018, The clinical respiratory journal.

[23]  Jianfei Qi,et al.  Ubiquitin ligases in oncogenic transformation and cancer therapy , 2017, Nature Reviews Cancer.

[24]  J. Kanwar,et al.  Recent advances in nanomedicine and survivin targeting in brain cancers. , 2018, Nanomedicine.

[25]  Shan Jiang,et al.  Expression of RNA-binding motif 10 is associated with advanced tumor stage and malignant behaviors of lung adenocarcinoma cancer cells , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[26]  K. Nan,et al.  LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC , 2016, Journal of Experimental & Clinical Cancer Research.

[27]  C. Kim,et al.  Pellino-1 confers chemoresistance in lung cancer cells by upregulating cIAP2 through Lys63-mediated polyubiquitination , 2016, Oncotarget.

[28]  Wei Li,et al.  Recent Advances on Small-Molecule Survivin Inhibitors , 2015, Current medicinal chemistry.

[29]  S. Lam,et al.  Elevated Expression of BIRC6 Protein in Non–Small-Cell Lung Cancers is Associated with Cancer Recurrence and Chemoresistance , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[30]  F. Oakley,et al.  NF-κB: a signal for cancer , 2005 .